BioMarin Pharmaceutical/ US09061G1013 /
| 2024-04-19 9:59:59 PM | Chg. -1.40 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 88.68USD | -1.55% | 148,679 Turnover: 13.22 mill. |
-Bid Size: - | -Ask Size: - | 16.72 bill.USD | - | 99.58 |
Assets
| 2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 269 | 284.5000 | 319.3000 | 523.5160 | 704.2070 | ||||||
| Intangible Assets | 180.3000 | 163 | 163.1000 | 156.5780 | 683.9960 | ||||||
| Long-Term Investments | - | - | - | 97.8560 | 425.6520 | ||||||
| Fixed Assets | - | - | - | 1,064.8240 | 2,639.7290 | ||||||
| Inventories | 130.1000 | 128.7000 | 162.6000 | 199.4520 | 271.6830 | ||||||
| Accounts Receivable | - | - | - | 144.4720 | 164.9590 | ||||||
| Cash and Cash Equivalents | 46.3000 | 180.5000 | 568.8000 | 875.4860 | 397.0400 | ||||||
| Current Assets | 469.8000 | 743.5000 | 1,137.4000 | 1,425.6290 | 1,089.6390 | ||||||
| Total Assets | 1,303.7000 | 1,601.6000 | 2,249.2000 | 2,490.4530 | 3,729.3680 | ||||||
Liabilities
| 2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 0.0000 | 0.0000 | 0.0000 | - | - | ||||||
| Long-term debt | - | - | - | 657.9760 | 662.2860 | ||||||
| Liabilities to Banks | 0.0000 | 23.4000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Provisions | - | 33.3000 | - | - | 143.5000 | ||||||
| Liabilities | 530.6000 | 585.9000 | 908.2000 | 962.5590 | 1,328.5210 | ||||||
| Share Capital | - | - | - | .1490 | .1620 | ||||||
| Total Equity | 773 | 1,015.8000 | 1,341 | 1,527.8940 | 2,400.8470 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 1,303.7000 | 1,601.6000 | 2,249.2000 | 2,490.4530 | 3,729.3680 | ||||||
Income Statement
| 2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 441.4000 | 500.7000 | 548.5000 | 751.0400 | 889.8950 | ||||||
| Depreciation (total) | 1.4000 | 18.7000 | 18.6000 | - | - | ||||||
| Operating Result | -33.9000 | -110.2000 | -156 | -92.8910 | -110.7020 | ||||||
| Interest Income | -5.4000 | -5 | -7.3000 | -30.7050 | -33.7430 | ||||||
| Income Before Taxes | -43.6000 | -118.3000 | -176.5000 | -124.8680 | -154.7240 | ||||||
| Income Taxes | 10.2000 | -3.9000 | -.2000 | 9.1010 | 17.0750 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | -53.8000 | -114.3000 | -176.4000 | -133.9690 | -171.7990 | ||||||
Per Share
Cash Flow
| 2011 US GAAP in mill. USD |
2012 US GAAP in mill. USD |
2013 US GAAP in mill. USD |
2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 18.8000 | 17.6000 | -59.6000 | -73.5390 | -221.6890 | ||||||
| Cash Flow from Investing Activities | -89.6000 | -195.6000 | -298.8000 | 194.5550 | -1,179.5980 | ||||||
| Cash Flow from Financing | 29 | 312.3000 | 746.7000 | 185.6890 | 927.9130 | ||||||
| Decrease / Increase in Cash | -41.8000 | 134.3000 | 388.3000 | 306.7050 | -478.4460 | ||||||
| Employees | 1,002 | 1,089 | 1,341 | 1,681 | 2,158 | ||||||
